Monthly Archives: September 2015

SGLT2 Inhibitor Phlorizin and Diabetic Heart Disease

The big news from the 2015 European Association for the Study of Diabetes (EASD) meeting in Stockholm was that diabetic patients treated with a sodium-glucose co-transporter 2 (SGLT2) inhibitor experienced better cardiovascular outcomes than those treated with placebo and standard of care. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG […]

By |September 28th, 2015|Diabetes|0 Comments

Measuring IGF1 – Future Direction for MS in the Clinical Lab

The peptide hormone insulin-like growth factor 1 (IGF1) is involved in a wide spectrum of biological processes.1 It is present in nanomolar amounts in blood. IGF-binding proteins modulate IGF1. Because the hormone is a marker for multiple disorders including osteoporosis, diabetes, obesity, neuromuscular disorders, growth hormone resistance and insulin resistance, accurate measurement of IGF1 levels […]

By |September 21st, 2015|Diabetes, Obesity|0 Comments

Metabolic Precursors of Hypertension on the Road to Cardiovascular Disease

A team of Korean scientists led by Minjoo Kim1 used ultra-high performance liquid chromatography coupled with mass spectrometry and multivariate data analysis to identify prehypertension-associated plasma metabolites. Prehypertension, defined by blood pressure measurements of 120-139 mmHg (systolic) and 80-89 mmHg (diastolic), can precede hypertension and atherosclerosis on the road to cardiovascular disease.

The researchers identified 53 […]

By |September 16th, 2015|Metabolic Disorder|0 Comments

Metabolic Changes Precede Clinical Symptoms in Type 2 Diabetes

Type 2 diabetes is primarily defined by elevated blood glucose, but other disease characteristics include central obesity and a lack of physical activity. The earliest molecular changes leading to type 2 diabetes are not well defined but are thought to include blood vessel dysfunction in addition to a rise in blood glucose. A research team […]

By |September 9th, 2015|Diabetes|0 Comments

Researchers Find CAIX Inhibition has Potential in Breast Cancer Subtypes

Solid tumors are characterized by their ability to thrive in conditions that favor a high intracellular pH and low extracellular pH.1 Carbonic anhydrase IX (CAIX) is an enzyme that is induced in response to hypoxia (low oxygen) and plays a role in maintaining intra- and extracellular pH balance. Overexpressed in many types of tumors including […]

By |September 2nd, 2015|Breast Cancer|0 Comments